{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.1","upperLimit":"19.9","value":"10.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"description":"Grade 3-4 post-procedural surgery-related toxicity rate is the percentage of participants experiencing at least one grade 3-4 adverse event (AE) during the post-procedural time frame of 14 days attributable to the surgical procedure based on NCI Common Toxicity Criteria for Adverse Events version 4 (CTCAEv4).","dispersionType":"90% Confidence Interval","groups":[{"description":"Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).\n\nTreatment directed based on tumor biopsy results requires classification of patients into 1 of 4 potential cohorts: O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status (negative versus positive) and epidermal growth factor receptor (EGFR) overexpression status (negative versus positive).","id":"OG000","title":"All Biopsied Participants"}],"paramType":"NUMBER","populationDescription":"The analysis dataset is comprised of all enrolled participants who underwent stereotactic biopsy.","reportingStatus":"POSTED","timeFrame":"2 weeks","title":"Grade 3-4 Post-Procedural Surgery-Related Toxicity Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}